Ebola vaccine development plan: ethics, concerns and proposed measures

Abstract

BackgroundThe global interest in developing therapies for Ebola infection management and its prevention is laudable. However the plan to conduct an emergency immunization program specifically for healthcare workers using experimental vaccines raises some ethical concerns. This paper shares perspectives on these concerns and suggests how some of them may best be addressed.DiscussionThe recruitment of healthcare workers for Ebola vaccine research has challenges. It could result in coercion of initially dissenting healthcare workers to assist in the management of EVD infected persons due to mistaken beliefs that the vaccine offers protection. It could also affect equity and justice. For example, where people who are not skilled health care professionals but who provide care to patients infected with Ebola (such as in home care settings) are not prioritized for vaccination. The possibility of study participants contracting Ebola infection despite the use of experimental vaccine, and the standard of care they would receive, needs to be addressed clearly, transparently and formalized as part of the ethics review process. Future access to study products in view of current status of the TRIPS agreement needs to be addressed. Finally, broad stakeholder engagement at local, regional and international levels needs to be promoted using available communication channels to engage local, regional and international support. These same concerns are applicable for current and future epidemics.SummarySuccessful Ebola vaccine development research requires concerted efforts at public dialogue to address misconceptions, equity and justice in participant selection, and honest discussions about risks, benefits and future access. Public dialogue about Ebola vaccine research plans is crucial and should be conducted by trusted locals and negotiated between communities, researchers and ethics committees in research study sites.

Genomics and High-Consequence Infectious Diseases: A Scoping Review of Emerging Science and Potential Ethical Issues

“…51 Since then, a voluntary WHO benefit-sharing framework has been established for pandemic influenza to promote equitable access to vaccines and therapies, but no such global benefit-sharing framework for Ebola or other high-consequence pathogens has been developed. 52,53 As a community that will benefit from the knowledge and applications derived from affected people and their participation in research, high-level isolation units could discuss how best to express support for the principles of benefit sharing and equitable access.…”

Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus

“…This particular vaccine is under trial in human (phase II/III). It provides protection against only EBOV and is clinically efficient in the clinical set up of ring vaccination format ( 38 , 83 , 84 ). EBOV and SUDV glycoproteins have been assimilated into a cAdVax vector (adenovirus-based vaccine).…”

Critical role of ethics in clinical management and public health response to the West Africa Ebola epidemic

“…Fears of cross-border transmission resulted in over 50 countries around the world issuing travel restrictions to and from EVD-affected countries. 9 Second, the epidemic garnered international support, including significant investment in the research and development of vaccines 10 and therapies 11 , 12 for EVD infection, although the response was slow and arguably inadequate. 13 , 14 Third, it stimulated debates at many international, regional, and national fora about compassionate access to experimental regimens for therapy during epidemics and alternative clinical trial designs to test the efficacy and effectiveness of vaccines and therapies.…”